Search

Author/Creator Gerber, David E.

2. A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG–ACRIN Cancer Research Group (E2511). Issue 1 (July 2015)

Authors:
Owonikoko, Taofeek K.; Dahlberg, Suzanne E.; Khan, Saad A.; Gerber, David E.; Dowell, Jonathan; Moss, Rebecca A.; Belani, Chandra P.; Hann, Christine L.; Aggarwal, Charu; Ramalingam, Suresh S.
Journal:
Lung cancer
Issue:
Volume 89:Issue 1(2015:Jul.)
Page Start:
66
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. (7th June 2017)

Authors:
Lieu, Christopher H.; Hidalgo, Manuel; Berlin, Jordan D.; Ko, Andrew H.; Cervantes, Andres; LoRusso, Patricia; Gerber, David E.; Eder, J. Paul; Eckhardt, S. Gail; Kapp, Amy V.; Tsuhako, Amy; McCall, Bruce; Pirzkall, Andrea; Uyei, Anne; Tabernero, Josep
Journal:
Oncologist
Issue:
Volume 22:Number 9(2017)
Page Start:
1024
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. (September 2017)

Authors:
Lieu, Christopher H.; Hidalgo, Manuel; Berlin, Jordan D.; Ko, Andrew H.; Cervantes, Andres; LoRusso, Patricia; Gerber, David E.; Eder, J. Paul; Eckhardt, S. Gail; Kapp, Amy V.; Tsuhako, Amy; McCall, Bruce; Pirzkall, Andrea; Uyei, Anne; Tabernero, Josep
Journal:
Oncologist
Issue:
Volume 22:Number 9(2017)
Page Start:
1024
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?. Issue 7 (July 2021)

Authors:
von Itzstein, Mitchell S.; Smith, Mary L.; Railey, Elda; White, Carol B.; Dieterich, Julianne S.; Garrett-Mayer, Liz; Bruinooge, Suanna S.; Freedman, Andrew N.; De Moor, Janet; Gray, Stacy W.; Park, Jason Y.; Yan, Jingsheng; Hoang, Anh Quynh; Zhu, Hong; Gerber, David E.
Journal:
JCO oncology practice
Issue:
Volume 17:Issue 7(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial. (18th August 2021)

Authors:
Murphy, Caitlin C.; Fullington, Hannah M.; Gerber, David E.; Bowman, Isaac Alex; Puligandla, Maneka; Dutcher, Janice P.; DiPaola, Robert S.; Haas, Naomi B.
Journal:
Cancer medicine
Issue:
Volume 10:Number 17(2021)
Page Start:
5917
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Association between immune-related adverse event timing and treatment outcomes. (31st December 2022)

Authors:
Hsiehchen, David; Naqash, Abdul Rafeh; Espinoza, Magdalena; Von Itzstein, Mitchell S.; Cortellini, Alessio; Ricciuti, Biagio; Owen, Dwight H.; Laharwal, Mehak; Toi, Yukihiro; Burke, Michael; Xie, Yang; Gerber, David E.
Journal:
Oncoimmunology
Issue:
Volume 11:Number 1(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗